Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01153646 · ClinicalTrials.gov registry record · Early Phase 1
Gene Transfer for HIV Using Autologous T Cells
A Early Phase 1 study, sponsored by City of Hope Medical Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT01153646 is a Early Phase 1 study that was terminated before completion, run by City of Hope Medical Center. The registered enrollment target is 5 participants.
The verdict
NCT01153646, a Early Phase 1 study, was terminated before completion, sponsored by City of Hope Medical Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a pilot study to determine the safety and feasibility of lentivirus-transduced T-cell immunotherapy in patients who have failed highly active anti-retrovirus therapy (HAART).
Interventions
- GENETIC pHIV7-shI-TAR-CCR5RZ treated CD4 cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01153646
The ClinicalTrials.gov registry entry for NCT01153646 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pHIV7-shI-TAR-CCR5RZ treated CD4 cells is the first listed.
NCT01153646 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01153646 about?
NCT01153646 is a clinical study titled "Gene Transfer for HIV Using Autologous T Cells". This is a pilot study to determine the safety and feasibility of lentivirus-transduced T-cell immunotherapy in patients who have failed highly active anti-retrovirus therapy (HAART).
What is the current status of trial NCT01153646?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2010-04. Estimated completion is 2011-01.
What interventions are being tested in trial NCT01153646?
The interventions under investigation include: pHIV7-shI-TAR-CCR5RZ treated CD4 cells (GENETIC).
Who is sponsoring clinical trial NCT01153646?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.